Valens’ 2Q26 results strengthened the near-term setup, with revenue and adjusted EBITDA ahead of guidance and management raising FY26 revenue expectations to $78M–$81M. The guidance increase is being driven primarily by stronger CIB adoption, particularly expanding VS3000 and VS6320 design-ins, rather than an earlier automotive ramp. Automotive profitability remains pressured by elevated testing costs, but all four A-PHY programs remain on track for initial revenue in 2027. Overall, improving CIB momentum, narrowing losses, and continued execution across the automotive pipeline provide better visibility into sequential growth and operating leverage through 2H26.